Array BioPharma | Date: 2015-05-14
Provided is Compound (I) or a pharmaceutically acceptable salt thereof, which is an inhibitor of TrkA kinase and is useful in the treatment of diseases which can be treated with a TrkA kinase inhibitor such as pain, cancer, inflammation and inflammatory diseases, neurodegenerative diseases, certain infectious diseases, Sjogrens syndrome, endometriosis, diabetic peripheral neuropathy, prostatitis, pelvic pain syndrome, diseases related to an imbalance of the regulation of bone remodeling, and diseases resulting from Connective Tissue Growth Factor aberrant signaling.
Astrazeneca and Array BioPharma | Date: 2016-11-10
The invention concerns pharmaceutical compositions containing a hydrogen sulphate salt of 6-(4-bromo-2-chloro-phenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxy-ethoxy)-amide and solvates, crystalline forms and amorphous forms thereof, to the use of said compositions as a medicament; and to processes for the preparation of said compositions.
Array BioPharma | Date: 2016-11-21
This invention relates to inhibitors of mitotic kinesins, particularly KSP, and methods for producing these inhibitors.
Array BioPharma | Date: 2017-03-22
A compound which is 6-chloro-7-(4-(4-chloro-2-methoxyphenethylcarbamoyl)-phenoxy)chroman-4-carboxylic acid, or a pharmaceutically acceptable salt thereof. Said compound is either a racemic mixture or a single enantiomer, preferably Enantiomer 2 of 6-chloro-7-(4-(4-chloro-2-methoxyphenethylcarbamoyl)phenoxy)chroman-4-carboxylic acid, or a pharmaceutically acceptable salt thereof, in particular its sodium salt. Said compound for use in treating an immunologic disorder in a mammal.
Array BioPharma and Genentech | Date: 2016-01-13
The present invention provides compounds, including resolved enantiomers, resolved diastereomers, solvates and pharmaceutically acceptable salts thereof, comprising the Formula I for use in oral dosage forms: Also provided are oral dosage forms comprising these compounds, methods of using the compounds and oral dosage forms of this invention as AKT protein kinase inhibitors and for the treatment of hyperproliferative diseases such as cancer. Further provided are intermediate compounds from the synthesis of these compounds.
Genentech and Array BioPharma | Date: 2016-02-26
Disclosed are crystalline forms of (R)N-(4-(3-aminopiperidin-1-yl)-5-bromo-1H-pyrrolo[2,3-b]pyridin-3-yl)cyclopropanecarboxamide, and salts, solvates, and hydrates thereof, and pharmaceutical compositions, formulations and a process of manufacturing thereof.
Array BioPharma | Date: 2016-10-12
Provided are compounds of Formula I^(2), R^(3), R^(13) , L and D^(2) are as defined in the specification, which are useful in the treatment and/or prevention of diseases or disorders mediated by deficient levels of glucokinase activity or which can be treated by activating glucokinase including, but not limited to, diabetes mellitus, impaired glucose tolerance, IFG (impaired fasting glucose) and IFG (impaired fasting glycemia), as well as other diseases and disorders such as those discussed herein.
Array BioPharma | Date: 2016-10-19
Provided are compositions and methods useful for modulation of signaling through the Toll-like receptors TLR7 and/or TLR8. The compositions and methods have use in the treatment of autoimmunity, inflammation allergy, asthma, graft rejection, graft versus host disease, infection, sepsis, cancer and immunodeficiency.
Array BioPharma | Date: 2016-01-05
Compounds of Formula I are useful for inhibition of CHK1 and/or CHK2. Methods of using compounds of Formula I and stereoisomers and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.
Array BioPharma | Date: 2016-05-31
A combination of a CHK1 inhibitor and a WEE1 inhibitor are provided.